ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema

Phase 3

Completed

Conditions: Macular Edema

Interventions: Procedure: Laser Photocoagulation
Drug: Dexamethasone

First Posted Date: 2014-04-23

Last Posted Date: 2020-11-17

Lead Sponsor: Allergan

Target Recruit Count: 284

Registration Number: NCT02121262

Locations: 🇨🇳
Wenzhou Ophthalmic Centre, Wenzhou, Zhejiang, China
🇵🇭
Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines
🇨🇳
Beijing Hospital, Beijing, Beijing, China

and more 15 locations

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Phase 4

Completed

Conditions: Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions: Drug: carboxymethylcellulose 0.5%/glycerin 0.9%
Drug: sodium hyaluronate 0.18%

First Posted Date: 2014-04-21

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 80

Registration Number: NCT02117687

OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Normal Saline
Biological: onabotulinumtoxinA

First Posted Date: 2014-04-16

Last Posted Date: 2017-12-19

Lead Sponsor: Allergan

Target Recruit Count: 258

Registration Number: NCT02116361

Locations: 🇺🇸
Schuster Medical Research Institute, Sherman Oaks, California, United States
🇺🇸
InSite Clinical Research, DeSoto, Texas, United States
🇺🇸
Zain Research LLC, Richland, Washington, United States

and more 32 locations

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%
Drug: travoprost 0.004%
Drug: hypromellose 0.3%
Drug: timolol 0.5%

First Posted Date: 2014-03-27

Last Posted Date: 2016-01-14

Lead Sponsor: Allergan

Target Recruit Count: 100

Registration Number: NCT02097719

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Phase 3

Terminated

Conditions: Urinary Incontinence
Urinary Bladder
Overactive

Interventions: Biological: BOTOX®

First Posted Date: 2014-03-26

Last Posted Date: 2022-12-28

Lead Sponsor: Allergan

Target Recruit Count: 56

Registration Number: NCT02097121

Locations: 🇫🇷
Duplicate_CHU Bordeaux-Hopital Pellegrin /ID# 237392, Bordeaux, France
🇩🇪
Evangelisches Krankenhaus Bielefeld /ID# 235234, Bielefeld, Germany
🇨🇦
Alberta Children's Hospital /ID# 237510, Calgary, Alberta, Canada

and more 36 locations

A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

Phase 3

Completed

Conditions: Erythema
Rosacea

Interventions: Drug: Oxymetazoline HCL Cream 1.0%

First Posted Date: 2014-03-24

Last Posted Date: 2019-11-18

Lead Sponsor: Allergan

Target Recruit Count: 440

Registration Number: NCT02095158

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 2

Terminated

Conditions: Macular Degeneration
Geographic Atrophy

Interventions: Other: Sham
Drug: 400 µg Brimonidine Implant

First Posted Date: 2014-03-14

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 310

Registration Number: NCT02087085

Locations: 🇺🇸
Northern California Retina Vitreous Associates, Mountain View, California, United States
🇺🇸
Retinal Consultants of Arizona, Ltd., Retinal Research Institute, Phoenix, Arizona, United States
🇺🇸
Raj K. Maturi, MD, Indianapolis, Indiana, United States

and more 37 locations

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Phase 3

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: AGN-229666

First Posted Date: 2014-03-10

Last Posted Date: 2016-03-14

Lead Sponsor: Allergan

Target Recruit Count: 140

Registration Number: NCT02082262

Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

Completed

Conditions: Urinary Incontinence

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2014-02-27

Last Posted Date: 2017-12-15

Lead Sponsor: Allergan

Target Recruit Count: 55

Registration Number: NCT02072928

Locations: 🇧🇪
CHU de Liège, Esneux, Belgium
🇧🇪
UZA, Edegem, Belgium
🇧🇪
Maria Ziekenhuis Noord-Limburg, Overpelt, Belgium

and more 3 locations

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.03%

First Posted Date: 2014-02-13

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 263

Registration Number: NCT02061683

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy